Health authorities are implementing a targeted vaccination initiative aimed at protecting one million teenagers and young adults against meningitis B infection. The program focuses on groups deemed to face the highest immediate risk of disease, including Year 13 pupils and those beginning university or residential further education this autumn.
Meningitis is an infection affecting the protective membranes surrounding the brain and spinal cord. While the condition can develop in any age group, it occurs most frequently in babies, young children, teenagers, and young adults. The infection can result from either bacterial or viral causes, with bacterial meningitis being less common but more severe than its viral counterpart. Meningococcal disease, a bacterial form, can progress to life-threatening conditions including blood poisoning and invasive meningitis, where infection enters the bloodstream or brain linings. In 2024-2025, there were 378 cases of invasive meningococcal disease recorded according to official statistics.
Symptoms of meningitis include sudden high fever, severe headache, neck stiffness, vomiting, diarrhea, joint and muscle pain, sensitivity to light, cold extremities, seizures, confusion, and extreme drowsiness. A characteristic rash that does not fade when pressed with glass may also appear. Medical attention should be sought immediately if symptoms develop.
Transmission occurs primarily through close personal contact involving exchange of saliva, such as through coughing, sneezing, kissing, or sharing drinks and vaping devices. Some individuals carry the bacteria asymptomatically but can transmit it to others. The disease tends to peak during October and November annually. University settings and other venues with large congregations of people face elevated outbreak risk.
Two primary vaccines provide protection against major meningitis causes. The MenACWY vaccine protects against four meningococcal groups and is offered to 14-year-olds, with free access available until age 25. The MenB vaccine protects against meningococcal group B and is recommended starting at eight weeks of age. Several other vaccinations, including those against pneumococcal bacteria and measles-mumps-rubella-chickenpox, offer additional protection. Vaccine experts recommend government consideration of routine MenB vaccination for all teenagers around age 15. Individuals in close contact with diagnosed cases can receive antibiotics as a preventive measure. Early medical treatment for meningitis symptoms is critical for positive outcomes.
Article Attribution | Read More at Article Source
Article summary produced by Claude AI